Suppr超能文献

使用适配体对小细胞肺癌细胞进行分子识别。

Molecular recognition of small-cell lung cancer cells using aptamers.

作者信息

Chen Hui William, Medley Colin D, Sefah Kwame, Shangguan Dihua, Tang Zhiwen, Meng Ling, Smith Josh E, Tan Weihong

机构信息

Shands Cancer Center, Department of Chemistry, UF Genetics Institute and McKnight Brain Institute, University of Florida, Gainesville, FL 32611-7200, USA.

出版信息

ChemMedChem. 2008 Jun;3(6):991-1001. doi: 10.1002/cmdc.200800030.

Abstract

Early diagnosis is the way to improve the rate of lung cancer survival, but is almost impossible today due to the lack of molecular probes that recognize lung cancer cells sensitively and selectively. We developed a new aptamer approach for the recognition of specific small-cell lung cancer (SCLC) cell-surface molecular markers. Our approach relies on cell-based systematic evolution of ligands by exponential enrichment (cell-SELEX) to evolve aptamers for whole live cells that express a variety of surface markers representing molecular differences among cancer cells. When applied to different lung cancer cells including those from patient samples, these aptamers bind to SCLC cells with high affinity and specificity in various assay formats. When conjugated with magnetic and fluorescent nanoparticles, the aptamer nanoconjugates could effectively extract SCLC cells from mixed cell media for isolation, enrichment, and sensitive detection. These studies demonstrate the potential of the aptamer approach for early lung cancer detection.

摘要

早期诊断是提高肺癌生存率的途径,但由于缺乏能灵敏且选择性地识别肺癌细胞的分子探针,目前几乎无法实现。我们开发了一种新的适体方法来识别特定的小细胞肺癌(SCLC)细胞表面分子标记物。我们的方法依赖基于细胞的指数富集配体系统进化技术(细胞SELEX),来为表达各种代表癌细胞间分子差异的表面标记物的全活细胞进化适体。当应用于包括患者样本来源的不同肺癌细胞时,这些适体在各种检测形式中都能以高亲和力和特异性与SCLC细胞结合。当与磁性和荧光纳米颗粒偶联时,适体纳米缀合物能够从混合细胞培养基中有效提取SCLC细胞,用于分离、富集和灵敏检测。这些研究证明了适体方法在早期肺癌检测中的潜力。

相似文献

1
Molecular recognition of small-cell lung cancer cells using aptamers.
ChemMedChem. 2008 Jun;3(6):991-1001. doi: 10.1002/cmdc.200800030.
2
Selection of DNA aptamers recognizing small cell lung cancer using living cell-SELEX.
Analyst. 2011 Apr 7;136(7):1310-2. doi: 10.1039/c0an00962h. Epub 2011 Feb 14.
3
Generating aptamers for recognition of virus-infected cells.
Clin Chem. 2009 Apr;55(4):813-22. doi: 10.1373/clinchem.2008.113514. Epub 2009 Feb 26.
4
Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells.
Anal Chem. 2006 May 1;78(9):2918-24. doi: 10.1021/ac052015r.
5
Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells.
Anal Chem. 2007 Apr 15;79(8):3075-82. doi: 10.1021/ac062151b. Epub 2007 Mar 10.
6
Identification of liver cancer-specific aptamers using whole live cells.
Anal Chem. 2008 Feb 1;80(3):721-8. doi: 10.1021/ac701962v. Epub 2008 Jan 5.
7
Selection of DNA aptamers with affinity for pro-gastrin-releasing peptide (proGRP), a tumor marker for small cell lung cancer.
Appl Biochem Biotechnol. 2013 Jan;169(1):250-5. doi: 10.1007/s12010-012-9956-5. Epub 2012 Nov 21.
8
Selection of aptamers for molecular recognition and characterization of cancer cells.
Anal Chem. 2007 Jul 1;79(13):4900-7. doi: 10.1021/ac070189y. Epub 2007 May 27.
9
Development of Cell-Specific Aptamers: Recent Advances and Insight into the Selection Procedures.
Molecules. 2017 Nov 27;22(12):2070. doi: 10.3390/molecules22122070.
10
Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells.
Analyst. 2009 Sep;134(9):1808-14. doi: 10.1039/b904476k. Epub 2009 Jul 1.

引用本文的文献

1
The Application of Aptamer and Research Progress in Liver Disease.
Mol Biotechnol. 2024 May;66(5):1000-1018. doi: 10.1007/s12033-023-01030-4. Epub 2024 Feb 2.
2
The application of Aptamer in biomarker discovery.
Biomark Res. 2023 Jul 19;11(1):70. doi: 10.1186/s40364-023-00510-8.
3
Aptamers and antibodies: rivals or allies in cancer targeted therapy?
Explor Target Antitumor Ther. 2021;2(1):107-121. doi: 10.37349/etat.2021.00035. Epub 2021 Feb 28.
4
Aptasensors versus immunosensors-Which will prevail?
Eng Life Sci. 2022 Jan 13;22(3-4):319-333. doi: 10.1002/elsc.202100148. eCollection 2022 Mar.
7
Metal-Organic Framework Nanocarriers for Drug Delivery in Biomedical Applications.
Nanomicro Lett. 2020 May 2;12(1):103. doi: 10.1007/s40820-020-00423-3.
8
Overview of the Therapeutic Potential of Aptamers Targeting Coagulation Factors.
Int J Mol Sci. 2021 Apr 9;22(8):3897. doi: 10.3390/ijms22083897.
9
Novel Aptamers Selected on Living Cells for Specific Recognition of Triple-Negative Breast Cancer.
iScience. 2020 Apr 24;23(4):100979. doi: 10.1016/j.isci.2020.100979. Epub 2020 Mar 12.

本文引用的文献

1
Optimization and modifications of aptamers selected from live cancer cell lines.
Chembiochem. 2007 Apr 16;8(6):603-6. doi: 10.1002/cbic.200600532.
2
Cancer statistics, 2007.
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66. doi: 10.3322/canjclin.57.1.43.
3
Molecular signatures of lung cancer--toward personalized therapy.
N Engl J Med. 2007 Jan 4;356(1):76-8. doi: 10.1056/NEJMe068218.
4
A five-gene signature and clinical outcome in non-small-cell lung cancer.
N Engl J Med. 2007 Jan 4;356(1):11-20. doi: 10.1056/NEJMoa060096.
5
Changing face of small-cell lung cancer: real and artifact.
J Clin Oncol. 2006 Oct 1;24(28):4526-7. doi: 10.1200/JCO.2006.07.3841.
6
Aptamers evolved from live cells as effective molecular probes for cancer study.
Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):11838-43. doi: 10.1073/pnas.0602615103. Epub 2006 Jul 27.
7
Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells.
Anal Chem. 2006 May 1;78(9):2918-24. doi: 10.1021/ac052015r.
8
Small-cell lung cancer.
Lancet. 2005;366(9494):1385-96. doi: 10.1016/S0140-6736(05)67569-1.
9
Clinical practice. Lung cancer screening.
N Engl J Med. 2005 Jun 30;352(26):2714-20. doi: 10.1056/NEJMcp042630.
10
Flow cytometric enrichment for respiratory epithelial cells in sputum.
Cytometry A. 2004 Jul;60(1):1-7. doi: 10.1002/cyto.a.20041.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验